Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TrivarXASX:TRI -2.50% 3-Year ROIIC % is 33.49 as of Jun. 2025, which is 150% above its 10-year median of 13.41. The stock has 2 warning signs investors should review. Among 618 Healthcare Providers & Services companies, TrivarX ranks better than 79.94% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
TrivarX's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 33.49%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for TrivarX's 3-Year ROIIC % or its related term are showing as below:
ASX:TRI's 3-Year ROIIC % is ranked better than 79.94% of 618
companies
in the Healthcare Providers & Services industry
Industry Median: 3.37
vs ASX:TRI: 33.49
TrivarX (ASX:TRI) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TrivarX 3-Year ROIIC % Related Terms
TrivarX 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for TrivarX's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRI vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, TrivarX's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TrivarX 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TrivarX's 3-Year ROIIC % falls into.
TrivarX's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.039 (Jun. 2025) - -3.638 (Jun. 2022) )
/
( 12.444 (Jun. 2025) - 7.669 (Jun. 2022) )
=
1.599
/
4.775
=
33.49%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TrivarX (ASX:TRI) has a 3-Year ROIIC % of 33.49 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TrivarX and its competitors. This is 150% above median its historical median of 13.41. According to the industry distribution chart, TrivarX ranks #124 out of 618 companies in the Healthcare Providers & Services industry, placing it in the top 20.1%.
Is TrivarX's 3-Year ROIIC % too high?
TrivarX's current 3-Year ROIIC % of 33.49 is 150% above median its 10-year median of 13.41. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.37. TrivarX's value of 33.49 is 893.8% above this industry median. Based on the distribution chart, TrivarX ranks #124 out of 618 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does TrivarX's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, TrivarX ranks #124 out of 618 companies for 3-Year ROIIC %. This places TrivarX in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.37. TrivarX's value of 33.49 is 893.8% above this benchmark. While the company's 10-year median is 13.41 vs. the industry median of 3.37, TrivarX has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.37, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TrivarX's current 3-Year ROIIC % of 33.49 is 893.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TrivarX and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TrivarX's current 3-Year ROIIC % is 33.49, which is 150% above median its own 10-year median of 13.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TrivarX stock overvalued right now?
TrivarX (ASX:TRI) has a current 3-Year ROIIC % of 33.49. The current 3-Year ROIIC % is 33.49, which is 150% above median its 10-year median of 13.41 and 893.8% above the Healthcare Providers & Services industry median of 3.37. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For TrivarX (ASX:TRI), the current 3-Year ROIIC % is 33.49 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx's clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability. The Company has one operating segment, being the research, development and commercialisation of its software asaService product, and two geographical locations, being Australia and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRI has been successfully added to your 
